Seyres, Denis http://orcid.org/0000-0002-2066-6980
Cabassi, Alessandra
Lambourne, John J.
Burden, Frances
Farrow, Samantha
McKinney, Harriet
Batista, Joana
Kempster, Carly
Pietzner, Maik
Slingsby, Oliver
Cao, Thong Huy
Quinn, Paulene A.
Stefanucci, Luca
Sims, Matthew C.
Rehnstrom, Karola
Adams, Claire L.
Frary, Amy
Ergüener, Bekir
Kreuzhuber, Roman
Mocciaro, Gabriele
D’Amore, Simona
Koulman, Albert
Grassi, Luigi
Griffin, Julian L.
Ng, Leong Loke
Park, Adrian
Savage, David B.
Langenberg, Claudia
Bock, Christoph
Downes, Kate
Wareham, Nicholas J.
Allison, Michael
Vacca, Michele
Kirk, Paul D. W.
Frontini, Mattia
Funding for this research was provided by:
British Heart Foundation Cambridge Centre of Excellence
MRC Clinical Research Training Fellowships (MR/R002363/1)
Wellcome Trust (WT 107064)
MRC Metabolic Disease Unit (MRC_MC_UU_12012.1)
The National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and NIHR Rare Disease Translational Research Collaboration
NHS Health Education England
Medical Research Council (MC_UU_00002/13)
British Heart Foundation (FS/18/53/33863)
NIHR Cambridge Biomedical Research Centre
Isaac Newton fellowship
NIHR Leicester Biomedical Research Centre and the John and Lucille Van Geest Foundation
Article History
Received: 16 November 2021
Accepted: 25 February 2022
First Online: 12 March 2022
Declarations
:
: Obese individuals referred for obese surgery by the obesity clinic and lipodystrophy patient cared for by the National Severe Insulin Resistance Service, respectively, both based at Addenbrooke’s hospital, Cambridge University Hospitals were recruited to this study together with healthy individuals. Informed consent was obtained under the “Inherited Platelet Disorders” ethics (REC approval 10/H0304/66 for patients and 10/H0304/65 for healthy controls, NRES Committee East of England-Cambridge East). BluePrint work package 10 (WP10) volunteers (representing the blood donors, “BD”, cohort) were recruited amongst NHS Blood and Transplant donors after informed consent under the “A Blueprint of Blood Cells” ethical approval (REC approval 12/EE/0040 NRES Committee East of England-Hertfordshire). “BioNASH” Cohort consisted of 73 consecutive patients recruited at the NASH Service at the Cambridge University Hospital. All the patients had a clinical diagnosis of NAFLD (patients with alternate diagnoses and etiologies were excluded) and histology scored. This study was approved by the local ethics committee; all patients gave their informed consent for the use of data (biochemistry and clinical history) and samples for research purposes. The principles of the Declaration of Helsinki were followed.
: The authors declare that they have no competing interests.